MichaelRobertSavonaMD

Hematologic Oncology

Head, Hematology, Cellular Therapy and Stem Cell Transplantation Beverly and George Rawlings Director of Hematology Research Professor of Medicine and Cancer Biology

Join to view full profile

Dr. Savona is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Savona's full profile

Already have an account?

Office
3601 The Vanderbilt Clini
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 615-936-0605

Summary

Michael Savona is Chief of Hematology, Cellular Therapy and Stem Cell Transplantation, and Professor of Medicine and Cancer Biology at Vanderbilt University Medial Center. He graduated from Davidson College, served in the USAF, received his medical degree from Wake Forest University School of Medicine in 2002. He is board certified in hematology specializes in caring for patients with chronic myeloid disorders (e.g. myeloproliferative neoplasms, bone marrow failure syndromes, aplastic anemia, myelodysplasia, and acute myeloid leukemia). He has more than 100 publications and over 500 citings.

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California Davis HealthResidency, Internal Medicine, 2002 - 2005
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2002

Certifications & Licensure

TN State Medical License 2011 - 2026
AL State Medical License 2020 - 2020
MI State Medical License 2005 - 2012
TX State Medical License 2008 - 2011
CA State Medical License 2004 - 2006
American Board of Internal Medicine Hematology

Clinical Trials

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Start of enrollment: 2015 Jul 01
Active, not recruiting
Phase 1
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Start of enrollment: 2021 Feb 09
Active, not recruiting
Phase 1, Phase 2
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies Start of enrollment: 2021 Jun 14
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

113 citations
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Robert F. Cornell, Bonnie Ky, Brendan M. Weiss, Cherie N. Dahm, Deepak K. Gupta
Journal of Clinical Oncology. 2019-06-12
237 citations
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs
Christoph C. Carter, Adewunmi Onafuwa-Nuga, Lucy A. McNamara, James Riddell, Dale L. Bixby
Nature Medicine. 2010-04-01
301 citations
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckstein
The New England Journal of Medicine. 2020-01-08

Abstracts/Posters

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) ...
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous...
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
JAK2V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid LeukemiaClinically Relevant Abstract
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy
Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Translating Pathophysiological Advances Into Innovative Treatments for Myelodysplastic Syndromes and Related Myeloid Neoplasms
60th American Society of Hematology Annual Meeting - 11/30/2018

Authored Content

In Oral Maintenance Therapy in AML, Do All Roads Lead to the Epigenome?November 2020

Press Mentions

Form 8-K Forma Therapeutics Holdi for: May 26May 26th, 2022
CAR-T Therapy Ushering in a New Era of Precision Medicine for Patients with Chronic Lymphocytic LeukemiaMarch 11th, 2022
Clinicians, Researchers Continue Search for Better MDS/MPN TherapySeptember 8th, 2016
Join now to see all